109 related articles for article (PubMed ID: 19584823)
1. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants.
Bacigalupo A; Lamparelli T; Milone G; Sormani MP; Ciceri F; Peccatori J; Locasciulli A; Majolino I; Di Bartolomeo P; Mazza F; Sacchi N; Pollicheni S; Pinto V; Van Lint MT;
Bone Marrow Transplant; 2010 Feb; 45(2):385-91. PubMed ID: 19584823
[TBL] [Abstract][Full Text] [Related]
2. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG).
Bacigalupo A; Oneto R; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Romagnani C; Bruno B; Van Lint MT; Frassoni F
Bone Marrow Transplant; 2001 Dec; 28(12):1093-6. PubMed ID: 11803348
[TBL] [Abstract][Full Text] [Related]
3. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
4. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM).
Bacigalupo A; Oneto R; Bruno B; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Lombardi A; Frassoni F; Van Lint MT
Bone Marrow Transplant; 2001 Dec; 28(11):1041-5. PubMed ID: 11781614
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
6. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin.
Graziani F; Van Lint MT; Dominietto A; Raiola AM; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Fiorone M; Bruno B; Bacigalupo A
Haematologica; 2002 Sep; 87(9):973-8. PubMed ID: 12217810
[TBL] [Abstract][Full Text] [Related]
8. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
9. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
10. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML).
Zander AR; Kröger N; Schleuning M; Finke J; Zabelina T; Beelen D; Schwerdtfeger R; Baurmann H; Bornhäuser M; Ehninger G; Fauser AA; Kiehl M; Trenschel R; Ottinger HD; Bertz H; Berger J; Kolb HJ; Schaefer UW
Bone Marrow Transplant; 2003 Aug; 32(4):355-61. PubMed ID: 12900771
[TBL] [Abstract][Full Text] [Related]
11. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group.
Basara N; Baurmann H; Kolbe K; Yaman A; Labopin M; Burchardt A; Huber C; Fauser AA; Schwerdtfeger R
Bone Marrow Transplant; 2005 May; 35(10):1011-8. PubMed ID: 15821768
[TBL] [Abstract][Full Text] [Related]
12. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
13. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects.
Bacigalupo A
Bone Marrow Transplant; 2005 Feb; 35(3):225-31. PubMed ID: 15558041
[TBL] [Abstract][Full Text] [Related]
14. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.
Remberger M; Svahn BM; Mattsson J; Ringdén O
Transplantation; 2004 Jul; 78(1):122-7. PubMed ID: 15257050
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
16. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Rischewski J; Sonnenberg S; Ayuk F; Tögel F; Schade U; Fiegel H; Erttmann R; Löliger C; Zander AR
Bone Marrow Transplant; 2002 Apr; 29(8):683-9. PubMed ID: 12180114
[TBL] [Abstract][Full Text] [Related]
17. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose.
Sormani MP; Oneto R; Bruno B; Fiorone M; Lamparelli T; Gualandi F; Raiola AM; Dominietto A; Van Lint MT; Frassoni F; Bruzzi P; Bacigalupo A
Bone Marrow Transplant; 2003 Jul; 32(2):205-11. PubMed ID: 12838286
[TBL] [Abstract][Full Text] [Related]
18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
19. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder.
Podgorny PJ; Ugarte-Torres A; Liu Y; Williamson TS; Russell JA; Storek J
Biol Blood Marrow Transplant; 2010 Jul; 16(7):915-26. PubMed ID: 20226870
[TBL] [Abstract][Full Text] [Related]
20. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution.
Nakai K; Mineishi S; Kami M; Saito T; Hori A; Kojima R; Imataki O; Hamaki T; Yoshihara S; Ohnishi M; Kim SW; Ando T; Fumitoh A; Kanda Y; Makimoto A; Tanosaki R; Kanai S; Heike Y; Ohnishi T; Kawano Y; Wakasugi H; Takaue Y
Transplantation; 2003 Jun; 75(12):2135-43. PubMed ID: 12829926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
